Research programme: antigen processing-independent epitopes - Apitope Technology

Drug Profile

Research programme: antigen processing-independent epitopes - Apitope Technology

Alternative Names: API F-VIII; ATX-F8-117; ATX-F8-17; ATX-GD-450; ATX-GD-459; ATX-UV1; ATX-UV2; iATX Factor VIII

Latest Information Update: 15 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Apitope Technology
  • Class Peptides
  • Mechanism of Action Immunomodulators; Thyrotropin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Graves' disease; Haemophilia A
  • Research Uveitis

Most Recent Events

  • 15 Mar 2018 Early research is underway for Uveitis (Apitope Technology pipeline, March 2018)
  • 15 Mar 2018 Preclinical development is underway for Autoimmune disorders. Haemophilia A and Graves' disease (Apitope Technology pipeline, March 2018)
  • 15 Mar 2018 Antigen processing-independent epitopes - Apitope Technology is available for licensing as of 15 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top